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CLINICAL RESEARCH
Genetic and protein markers of CVD
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Aims It has been suggested that troponins and natriuretic peptides can be falsely elevated in subjects with impaired kidney
function because of decreased renal clearance. The value of these biomarkers in subjects with impaired kidney
function has therefore been debated. We tested in a population-based cohort study, first, whether high-sensitive
troponin T (hsTnT) and N-terminal pro-B-type natriuretic peptide (NT-pro-BNP) levels are cross-sectionally asso-
ciated with the estimated glomerular filtration rate (eGFR) and albuminuria, and secondly, whether these markers are




We included 8121 subjects from the PREVEND study with both values of hsTnT and NT-pro-BNP available.
High-sensitive troponin T .0.01 mg/L and NT-pro-BNP .125 ng/L were defined as elevated. We first performed
linear regression analyses with hsTnT and NT-pro-BNP as dependent variables. Next, we performed Cox-regression
analyses, studying the associations of hsTnT and NT-pro-BNP with incident cardiovascular events. Of our cohort,
6.7% had an elevated hsTnT and 12.2% an elevated NT-pro-BNP. Also, the estimated glomerular filtration rate, al-
buminuria, and ECG-assessed ischaemia and left ventricular hypertrophy were all significantly associated with hsTnT
and NT-pro-BNP in the linear regression analyses. Both hsTnT and NT-pro-BNP appeared associated with cardio-
vascular events, and these associations remained significant after adjustment for eGFR, albuminuria, age, gender and
conventional cardiovascular risk factors (P ¼ 0.03 and P, 0.001, respectively). Only a few subjects with markedly
reduced renal function were included. The results presented are therefore mainly valid for a population with
mildly impaired renal function.
Conclusion These data indicate that a finding of an increased hsTnT or NT-pro-BNP in subjects with chronic kidney disease
stages 1/3 should be taken seriously as a prognostic marker for a worse cardiovascular outcome and not be discarded
as merely a reflection of decreased renal clearance.
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Introduction
Recently various biomarkers related to subclinical cardiovascular
disease have drawn attention for clinical use in patients with
cardiovascular symptoms and in epidemiological research to
predict the cardiovascular prognosis. This applies among others
to troponins and N-terminal pro-B-type natriuretic peptides
(NT-pro-BNP).1–3 It has therefore been suggested that these
markers could be used in addition to ‘conventional’ cardiovascular
risk factors to improve the cardiovascular risk estimation.4,5
Cardiac troponin T (TnT) is a sensitive and specific marker of
ischaemic myocardial damage and is widely used as predictor of
cardiovascular events.1 Recently, a new, more sensitive troponin
assay has been released, which can measure substantially lower
concentrations than previous assays. High-sensitive troponin T
(hsTnT) has been shown to be a powerful predictor of mortality.6
Natriuretic peptides, including BNP and its equimolarly secreted
N-terminal fragment (NT-pro-BNP), are increased in relation to
cardiac stretch7 and left ventricular hypertrophy, and are estab-
lished biomarkers for guiding the diagnosis, prognosis and manage-
ment in patients with established cardiovascular disease and heart
failure.4,8,9 Plasma NT-pro-BNP has been shown to independently
predict the all-cause mortality and cardiovascular events.3
In subjects with decreased estimated glomerular filtration rate
(eGFR) or increased albuminuria, the use of these cardiac biomar-
kers has been debated. It has been suggested that especially in sub-
jects with impaired renal function BNP may be falsely elevated.
Because of decreased renal clearance, BNP is thought to be
increased, even when there are no overt signs of volume overload
or left ventricular hypertrophy.10–14 Similarly, it has been argued
that TnT levels are elevated in patients with impaired renal function
even when there is no evidence of coronary artery stenosis.15,16 On
the other hand, the predictive value of TnT and NT-pro-BNP for
cardiovascular events has been shown to be maintained in such
subjects.8,17,18 The association of urinary albumin excretion (UAE)
with hsTnT and NT-pro-BNP has yet not been studied.
We hypothesized that hsTnT and NT-pro-BNP are elevated in
subjects with lower eGFR or higher albuminuria, not because of
decreased renal clearance, but because these markers truly reflect
subclinical cardiac damage. We therefore tested in a population-
based cohort study, first, whether serum levels of hsTnT and
NT-pro-BNP are associated with eGFR and albuminuria, and with
minor ischaemic changes and/or left ventricular hypertrophy on
electrocardiography (ECG). Secondly, we studied whether these
cardiac biomarkers are associated with cardiovascular outcome,
independent of the eGFR and albuminuria.
Methods
Study design and population
This study was conducted among subjects who participate in the Preven-
tion of REnal and Vascular ENd-stage Disease (PREVEND) study, which
started in 1997. This prospective cohort study investigates the natural
course of albuminuria and its relation to renal and cardiovascular
disease. Details of the study protocol have been published elsewhere.19,20
In summary, all inhabitants of the city of Groningen aged 28–75
years were sent a questionnaire on demographics, disease history,
smoking habits, use of medication, and a vial to collect a
first-morning-void urine sample. Of these subjects, 40 856 responded
(47.8%). From these subjects, the PREVEND cohort was selected
with the aim to create a cohort enriched for the presence of high
albuminuria. After exclusion of patients with type 1 diabetes mellitus
(defined as requiring the use of insulin) and pregnant females
(defined by self-report), all subjects with a urinary albumin concentra-
tion .10 mg/L (7768) were invited, of which 6000 participated. Fur-
thermore, a randomly selected control group with a urinary albumin
concentration of ,10 mg/L (3394) was invited, of which 2592 partici-
pated. These 8592 subjects constitute the actual PREVEND cohort and
were studied in more detail.
For the current study, we excluded 471 subjects with no data on
hsTnT or NT-pro-BNP at baseline, leaving 8121 subjects for analysis,
which is also graphically shown in Figure 1. The PREVEND study was
approved by the medical ethics committee of our institution and
conducted in accordance with the guidelines of the Declaration of
Helsinki. All participants gave written informed consent.
Measurements and definitions
At the baseline visit anthropometrical measurements were performed,
and fasting blood samples were taken. In addition, subjects collected
urine for two consecutive periods of 24 h. The blood pressure was
measured in the supine position, every minute for 10 and 8 min,
respectively, with an automatic device (Dinamap XL Model 9300;
Johnson-Johnson Medical, Tampa, FL, USA). The blood pressure is
given as the mean of the last two recordings of both visits.
Concentrations of the total cholesterol and the plasma glucose were
measured using standard methods. Serum creatinine was measured by
dry chemistry (Eastman Kodak, Rochester, New York, USA), with an
intra-assay coefficient of variation of 0.9% and inter-assay coefficient
of variation of 2.9%. The urinary albumin concentration was measured
by nephelometry with a threshold of 2.3 mg/L and intra- and inter-
assay coefficients of variation of 2.2 and 2.6%, respectively (BNII;
Dade Behring Diagnostic, Marburg, Germany). The urinary albumin
excretion is given as the mean of the two 24-h urine collections. High-
sensitive troponin T (fifth generation cTnT assay) and NT-pro-BNP
were all measured on the Roche Modular E170 (Roche Diagnostics,
Mannheim, Germany) with commercially available kits.3 An increased
level of hsTnT was defined as a level .0.01 mg/L.21 An increased
level of NT-pro-BNP was defined when the level at baseline was
.125 ng/L.22–24
Participants were considered as smoking when they had smoked in
the previous year according to the questionnaire. Cardiovascular
history was defined as self-reported myocardial infarction, percutan-
eous transluminal coronary angioplasty, coronary artery bypass
graft or cerebrovascular accident. Hypertension was defined as systolic
blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg,
or the use of antihypertensive medication according to self-report or
to pharmacy data following the JNC-7 criteria. Hyperlipidaemia was
defined as a cholesterol level .6.0 mmol/L when a history of hyperlip-
idaemia was present, or a cholesterol level of .6.5 mmol/L when a
history of hyperlipidaemia was absent, or the use of lipid-lowering
drugs. Diabetes was defined as a fasting glucose level .7.0 mmol/L
or non-fasting glucose level of .11.1 mmol/L or the use of anti-
diabetic medication following the ADA criteria. The estimated glom-
erular filtration rate was estimated using the chronic kidney disease
(CKD)-EPI equation.25 The body mass index was calculated as the
ratio of the weight and the square of the height (weight/height2).
Minor ischaemic changes on the ECG were defined using the Minne-
sota code classification system for electrocardiographic findings, codes
1, 4, and 5.23 Left ventricular hypertrophy on the ECG was defined
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using the Cornell criteria: RaVL + SV3 (with 6 mm added in women)
× the QRS duration. A threshold of 2440 mm*ms was used to identify
left ventricular hypertrophy.26,27
Cardiovascular events
For the cardiovascular outcome, we used the incidence of the combined
outcome of the cardiovascular morbidity and mortality. The date and
cause of death were obtained by record linkage with the Dutch
Central Bureau of Statistics. Information on hospitalization for cardio-
vascular morbidity was obtained from PRISMANT, the Dutch national
registry of hospital discharge diagnoses. All data were coded according
to the International Classification of Diseases, 9th revision and the clas-
sification of interventions. For this study, cardiovascular events were
defined as incident acute myocardial infarction (ICD-code 410), acute
and subacute ischaemic heart disease (411), and coronary artery
bypass grafting or percutaneous transluminal coronary angioplasty.
Statistical analysis
All calculations were performed with the SPSS version 18.0 software.
Continuous data are reported as mean+ SD. In the case of a skewed
distribution, the median with the inter-quartile range is presented. Dif-
ferences between groups for continuous data were tested by Student’s
t-test or a Mann–Whitney rank test in case of skewed distribution. Dif-
ferences between groups for proportions were tested with a x2 test.
We first performed cross-sectional analyses with hsTnT and
NT-pro-BNP as dependent variables in multivariable linear regression
analyses. In these analyses, the eGFR and UAE were entered as inde-
pendent variables (model 1), with subsequent adjustment for age and
gender (model 2) and traditional cardiovascular risk factors (model 3),
and finally with additional adjustment for ECG-assessed minor cardiac
ischaemia and left ventricular hypertrophy (model 4). Because both
cardiac variables, hsTnT and NT-pro-BNP, are not normally distribu-
ted, these variables were logarithmically transformed to meet the
assumptions for linear regression analyses. The relation between
hsTnT, respectively, NT-pro-BNP and the GFR and UAE was compat-
ible with a linear relationship.
A KDIGO-initiated working group recently proposed that CKD
should be defined on the basis of the level of the eGFR as well as
on the level of albuminuria.28 The prevalence of having a higher
hsTnT and NT-pro-BNP was therefore studied with logistic regression
analyses in relation to clinically relevant categories of the eGFR as well
as UAE29 and compared with the prevalence in a GFR × albuminuria
reference category assumed to be at the lowest risk for cardiovascular
events (eGFR 90–104 mL/min/1.73 m2 and UAE ,10 mg/24 h).30–32
In case eGFR × albuminuria categories contained ,20 subjects, no
odds ratios (OR) were calculated because of insufficient power.
We next performed univariable and multivariable Cox-regression
analyses to investigate the association of hsTnT or NT-pro-BNP
with incident cardiovascular events, respectively. Univariable Cox-
regression analyses were performed for hsTnT and NT-pro-BNP
(model 1), respectively, with subsequent adjustment for the eGFR
and UAE (model 2), age and gender (model 3), and finally with additi-
onal adjustment for traditional cardiovascular risk factors (model 4).
Furthermore, hsTnT and NT-pro-BNP were simultaneously entered
in the various models. In addition, it was investigated whether there
was an interaction between hsTnT and NT-pro-BNP on the one
hand and the eGFR on the other to check whether a possible relation
between these cardiac damage biomarkers and cardiovascular events is
indeed independent of renal function. This was done by adding the
interaction term hsTnT (or NT-pro-BNP) × eGFR to the full adjusted
model containing also both variables as single terms. For Cox-
regression analyses, survival time was defined as the period from the
date of urine collection of the participant to the date of the first car-
diovascular event or 1 January 2009 (end of follow-up). Subjects were
censored in case they died or moved to an unknown destination.
Since the PREVENDstudy is enriched for subjectswith higher albumin-
uria levels, sensitivity analyses were performed using weighted analyses,
Figure 1 Flow chart of the PREVEND study.
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adjusting for the study design.33 Furthermore, the aforementioned
analyses were also performed only in subjects with chronic kidney
disease (eGFR ,60 mL/min/1.73 m2 and/or albuminuria .30 mg/24 h).
For all analyses, a two-sided P-value ,0.05 was considered to
indicate statistical significance.
Results
For the present analyses, 8121 subjects were included of whom
data on both hsTnT as well as NT-pro-BNP were available
(Figure 1). Approximately 50% of the cohort consisted of male sub-
jects, with a mean age of 49.3+12.7 years (Table 1). Our study
population comprised 1505 subjects (18.5% of the overall popula-
tion) with CKD. Of these subjects 231 (2.8%) had CKD stage 1
(eGFR .90 mL/min/1.73 m2 and UAE .30 mg/day), 800 (9.9%)
stage 2 (eGFR 60–90 mL/min/1.73 m2, and UAE .30 mg/day),
419 (5.2%) stage 3a (eGFR 45–60 mL/min/1.73 m2), 46 (0.6%)
stage 3b (eGFR 30–45 mL/min/1.73 m2), and 9 (1.0%) stage 4 or
5 (eGFR 15–30 and ,15 mL/min/1.73 m2, respectively). More
detailed information on the distribution over the various eGFR
× albuminuria categories is given in Supplementary material
online, Tables S1 and S2. High-sensitive troponin T was
.0.01 mg/L in 544 subjects (6.7%) and NT-pro-BNP was
.125 ng/L in 984 subjects (12.1%). Subjects with a high hsTnT,
as well as subjects with a high NT-pro-BNP, had a worse cardio-
vascular risk profile and had more ECG-assessed ischaemic
changes and left ventricular hypertrophy. Subjects with high
cardiac biomarkers had also more often a lower eGFR and
higher albuminuria.
The association of high-sensitive troponin
T and N-terminal pro-B-type natriuretic
peptide with estimated glomerular
filtration rate and albuminuria
The estimated glomerular filtration rate and UAE were associated
with hsTnT (P, 0.001) (Table 2) and NT-pro-BNP (P, 0.001)
(Table 3) (model 1), even after adjustment for age and gender
(model 2) and further adjustment for cardiovascular risk factors
(model 3) and the presence of ischaemic changes and left ventricu-
lar hypertrophy on ECG (model 4).
The OR of having an elevated hsTnT (.0.01 mg/L) or an
elevated NT-pro-BNP (.125 ng/L) is given in Figure 2, for each
eGFR × UAE category compared with the reference category of
eGFR 90–104 mL/min/1.73 m2 and UAE ,10 mg/24 h (see also
Supplementary material online, Tables S1 and S2). These figures
and tables show that the risk increased with a lower eGFR as
well as with higher albuminuria. Of note, in not all eGFR×
albuminuria categories an OR is given, because of a lack of
power in these cells (subject number in a cell ,20).
The association of high-sensitive troponin
T and N-terminal pro-B-type natriuretic
peptide with cardiovascular events
During follow-up 583 cardiovascular events (7.2%) were observed,
which consisted of incident acute myocardial infarction (n ¼ 243),
acute and subacute ischaemic heart disease (n ¼ 178), and
coronary artery bypass grafting (n ¼ 67) or percutaneous trans-
luminal coronary angioplasty (n ¼ 95). High-sensitive troponin T
(Table 4) and NT-pro-BNP (Table 5) were associated with incident
cardiovascular events, both univariably (model 1) as well as after
adjustment for eGFR and albuminuria (model 2) and further adjust-
ment for age and gender (model 3) and cardiovascular risk factors
(model 4). Of note, the eGFR and UAE were not significantly asso-
ciated with the cardiovascular outcome in this last multivariate
model (model 4). Figure 3 shows adjusted hazard ratios (HR) for
cardiovascular events according to CKD status and low or high
hsTnT or BNP. A higher level of NT-pro-BNP is associated with
a higher risk of cardiovascular events, in non-CKD (adjusted HR:
1.49, P-value 0.006) as well as CKD patients (adjusted HR: 1.55,
P-value 0.008). A higher level of hsTnT was similarly associated
with higher risk in the unadjusted analyses in non-CKD (HR: 3.3;
P-value , 0.001) as well as CKD (HR: 2.7; P-value ,0.001),
whereas in the adjusted analyses a higher level of hsTnT was
only associated with a higher risk in subjects with CKD (adjusted
HR: 1.53, P-value 0.008) (non-CKD, hsTnT adjusted HR: 0.92,
P-value 0.65).
We analysed whether there was an interaction between hsTnT
and NT-pro-BNP on the one hand and eGFR on the other in
their association with cardiovascular events in the full adjusted
model (model 4). No such interactions were found (P ¼ 0.78
and P ¼ 0.38, respectively).
Sensitivity analyses
Several sensitivity analyses were performed. First, even though
both hsTnT and NT-pro-BNP were entered simultaneously to
the various Cox-regression models, only NT-pro-BNP remained
significantly associated with cardiovascular events (Supplementary
material online, Table S3). Secondly, the aforementioned analyses
were repeated in subjects with chronic kidney disease only
(eGFR ,60 mL/min/1.73 m2 and/or UAE .30 mg/24 h). Cox-
regression analyses in these patients showed that hsTnT and
NT-pro-BNP were still associated with cardiovascular events in
crude as well as adjusted models (models 2–4) (Supplementary
material online, Tables S4 and S5). Thirdly, when all analyses
were repeated using weighted models, adjusting for the study
design, essentially similar results were obtained.
Discussion
We found that in this general population-based study both hsTnT
and NT-pro-BNP are inversely associated with the eGFR and posi-
tively associated with albuminuria. We, moreover, showed that
both cardiac damage biomarkers are still associated with cardiovas-
cular events after adjustment for eGFR, albuminuria, and cardiovas-
cular risk factors.
Our data of an increased hsTnT and NT-pro-BNP level in case
of a lower eGFR is in agreement with the literature.18,34 To our
knowledge, the association of hsTnT and NT-pro-BNP level with
albuminuria has yet not been studied specifically. The observation
that the associations of these cardiac biomarkers with high albu-
minuria is comparable with the association of these biomarkers
with a low eGFR may help shed new light on the assumption
that cardiac biomarkers such as NT-pro-BNP are elevated in
HsTnT and NT-pro-BNP in impaired renal function 2275
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Age (years) 49.3+12.7 48.2+12.2 64.2+9.8 ,0.001 47.9+12.0 59.4+12.6 ,0.001
Male (%) 49.8 47.7 78.9 ,0.001 51.0 42.0 ,0.001
BMI (kg/m2) 26.1+4.2 26.0+4.2 27.7+4.0 ,0.001 26.0+4.2 26.6+4.5 ,0.001
Smoking (%) 37.8 38.5 27.6 ,0.001 38.2 35.1 0.066
CVD history (%) 5.2 4.2 19.5 ,0.001 3.1 20.9 ,0.001
SBP (mmHg) 129.1+20.3 127.6+19.2 148.6+23.5 ,0.001 127.3+18.6 141.5+26.7 ,0.001
DBP (mmHg) 74.0+9.8 73.5+9.5 80.7+10.6 ,0.001 73.6+9.5 77.0+11.2 ,0.001
Antihypertensive medication (%) 16.7 14.4 44.7 ,0.001 12.7 42.7 ,0.001
Hypertension (%) 33.4 30.3 77.0 ,0.001 29.0 66.0 ,0.001
Glucose (mmol/L) 4.9+1.2 4.8+1.1 5.5+1.9 ,0.001 4.9+1.1 5.1+1.4 ,0.001
Glucose lowering medication (%) 1.6 1.2 6.8 ,0.001 1.3 3.4 ,0.001
Diabetes (%) 3.6 2.9 12.7 ,0.001 3.1 7.2 ,0.001
Cholesterol (mmol/L) 5.6+1.1 5.6+1.1 5.9+1.1 ,0.001 5.6+1.1 5.7+1.1 0.149
Lipid lowering medication (%) 4.1 3.7 9.8 0.173 3.2 10.2 0.022
Hyperlipidaemia (%) 26.6 25.6 40.1 ,0.001 25.3 36.7 ,0.001
Serum creatinine (mmol/L) 83.9+19.7 82.6+13.7 99.2+26.0 ,0.001 83.1+13.7 89.7+42.5 ,0.001
Serum hsTnT (mg/L) 0.003 (0.003–0.005) 0.003 (0.003–0.004) 0.01 (0.01–0.02) ,0.001 0.003 (0.003–0.004) 0.005 (0.003–0.01) ,0.001
Serum NT-pro-BNP (ng/L) 37.7 (16.8–73.8) 35.5 (15.9–68.3) 105.9 (42.2–285.7) ,0.001 31.7 (14.8–56.7) 195.5 (150.1–327.7) ,0.001
Minor ischaemic changes (%) 23.2 21.5 48.8 ,0.001 20.1 45.8 ,0.001
LVH according to Cornell (%) 2.3 1.8 10.2 ,0.001 1.6 7.2 ,0.001
eGFR (mL/min/1.73 m2) 83.9+15.5 85.0+14.8 68.9+16.7 ,0.001 85.3+14.7 73.8+17.4 ,0.001
eGFR,60 (mL/min/1.73 m2) (%) 5.9 4.4 27.9 ,0.001 4.1 19.2 ,0.001
UAE (mg/24 h) 9.4 (6.3–17.8) 9.1 (6.2–16.3) 23.1 (10.4–63.8) ,0.001 9.1 (6.3–16.1) 14.5 (7.3–41.0) ,0.001
UAE .30 (mg/24 h) 14.8 12.7 42.8 ,0.001 12.6 30.7 ,0.001
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CKD predominantly because of impaired renal clearance.13 If that
would be the explanation, hsTnT and NT-pro-BNP levels would
not be expected to be increased in case of higher albuminuria in-
dependent of the level of eGFR.
Our finding that these cardiac biomarkers are associatedwith car-
diovascular events, as well as that this association persisted after
adjusting for the level of the eGFR and albuminuria, is also in agree-
ment with data from other studies.8,17 The HR remained statistically
significant after further adjusting for cardiovascular risk factors, indi-
cating that these cardiac biomarkers can be used in subjects with
impaired renal function to predict their cardiovascular prognosis.
As the prevalence of ECG-assessed minor ischaemic changes and
left ventricular hypertrophy was higher in the high hsTnT and high
NT-pro-BNP groups, we argue that the biomarkers are increased
in subjects with a lower eGFR (and higher albuminuria), as they cor-
rectly reflect cardiac ischaemia and/or hypertrophy. It has indeed
been reported that the cardiovascular abnormalities in subjects
with impaired kidney function are due to more than just coronary
heart disease.35 Experimental models have shown that even a
modest resection of renal parenchyma causes left ventricular hyper-
trophy, cardiac fibrosis, and microvessel disease with wall thickening
of intramyocardial arterioles in the hypertrophied heart.36
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Table 3 Association between N-terminal pro-B-type natriuretic peptide (log-transformed) as dependent variable and
estimated glomerular filtration rate and urinary albumin excretion as independent variables (model 1), and additionally
age and gender (model 2), cardiovascular risk factors (model 3) and ECG abnormalities (model 4)
Variable Model 1 Model 2 Model 3 Model 4
St B P-value St B P-value St B P-value St B P-value
eGFR (mL/min/1.73 m2) 20.29 ,0.001 20.07 ,0.001 20.06 ,0.001 20.06 ,0.001
Ln UAE (mg/24 h) 0.10 ,0.001 0.11 ,0.001 0.09 ,0.001 0.09 ,0.001
Age (years) 0.33 ,0.001 0.35 ,0.001 0.33 ,0.001
Female (yes vs. no) 0.32 ,0.001 0.36 ,0.001 0.36 ,0.001
Smoking (yes vs. no) 0.02 0.12 0.01 0.13
Diabetes (yes vs. no) 20.04 ,0.001 20.04 ,0.001
CVD history (yes vs. no) 0.19 ,0.001 0.16 ,0.001
BMI (kg/m2) 20.13 ,0.001 20.11 ,0.001
SBP (mmHg) 0.12 ,0.001 0.09 ,0.001
Cholesterol (mmol/L) 20.16 ,0.001 20.16 ,0.001
Minor ischaemic ECG changes (yes vs. no) 0.10 ,0.001
LVH according to Cornell (yes vs. no) 0.07 ,0.001
UAE, urinary albumin excretion; CVD, cardiovascular disease; BMI, body mass index; SBP, systolic blood pressure; LVH, left ventricular hypertrophy (using Cornell criteria).
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Table 2 Association between high-sensitive troponin T (log-transformed) as a dependent variable and estimated
glomerular filtration rate and urinary albumin excretion as independent variables (model 1), and additionally age and
gender (model 2), cardiovascular risk factors (model 3) and ECG abnormalities (model 4)
Variable Model 1 Model 2 Model 3 Model 4
St B P-value St B P-value St B P-value St B P-value
eGFR (mL/min/1.73 m2) 20.31 ,0.001 20.16 ,0.001 20.16 ,0.001 20.16 ,0.001
Ln UAE (mg/24 h) 0.24 ,0.001 0.14 ,0.001 0.10 ,0.001 0.09 ,0.001
Age (years) 0.33 ,0.001 0.29 ,0.001 0.28 ,0.001
Female (yes vs. no) 20.26 ,0.001 20.24 ,0.001 20.24 ,0.001
Smoking (yes vs. no) 0.02 0.02 0.02 0.02
Diabetes (yes vs. no) 0.06 ,0.001 0.06 ,0.001
CVD history (yes vs. no) 0.06 ,0.001 0.05 ,0.001
BMI (kg/m2) 20.004 0.66 0.01 0.49
SBP (mmHg) 0.12 ,0.001 0.10 ,0.001
Cholesterol (mmol/L) 20.06 ,0.001 20.05 ,0.001
Minor ischaemic ECG changes (yes vs. no) 0.06 ,0.001
LVH according to Cornell (yes vs. no) 0.05 ,0.001
UAE, urinary albumin excretion; CVD, cardiovascular disease; BMI, body mass index; SBP, systolic blood pressure.
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A higher hsTnT and NT-pro-BNP in relation to both a lower eGFR
and higher albuminuria are, moreover, in line with recent data that
the eGFR and albuminuria independently of each other predict
cardiovascular mortality in subjects of the general population,29
in subjects selected for an increased cardiovascular risk30 and in
subjects with known CKD.31 The aforementioned observations
taken together indicate that a finding of an increased hsTnT or
NT-pro-BNP in a subject with a lower eGFR should be taken ser-
iously as a prognostic marker for a worse cardiovascular outcome
and not be discarded as merely the result of decreased renal
clearance.
The similarity of the association of hsTnT levels with both
ECG-assessed minor ischaemia as well left ventricular hypertrophy
in our study is striking. Although TnT elevation is assumed to be
the result of clinically silent myocardial necrosis and micro-
infarctions37 TnT has also been found to be elevated in patients
with heart failure in the absence of acute ischaemia 38,39 and in
CKD patients with left ventricular hypertrophy without myocardial
ischaemia.40 Our study also showed that NT-pro-BNP was not
only associated with left ventricular hypertrophy, but also with
ECG-assessed minor ischaemia. Experimental models have
shown that hypoxic myocardial tissue results in the production
of extra BNP, suggesting that BNP could potentially serve as a bio-
marker of myocardial ischaemia.41,42 These experimental data
were confirmed in a number of small-scale clinical studies, which
were recently summarized in a meta-analysis.43 These data indicate
that BNP is not only linked to left ventricular hypertrophy and
heart failure, but that there is a possible role for BNP also in the
diagnosis and management of myocardial ischaemia.
Our findings that the associations of the GFR and albuminuria
with cardiovascular events lose significance in the overall multivari-
able adjusted model although both hsTnT and NT-pro-BNP
remained significantly associated with cardiovascular event
suggest that both hsTnT and NT-pro-BNP may help to detect
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Table 4 Hazard ratios for cardiovascular events with high-sensitive troponin T as an independent variable in various
models adjusting for covariates
Variable Model 1 Model 2 Model 3 Model 4
HR P-value HR P-value HR P-value HR P-value
Ln hsTnT (mg/L) 2.15 ,0.001 1.86 ,0.001 1.25 0.002 1.18 0.03
eGFR (mL/min/1.73 m2) 0.98 ,0.001 0.99 0.21 0.99 0.08
Ln UAE (mg/24 h) 1.25 ,0.001 1.17 ,0.001 1.05 0.19
Age (years) 1.06 ,0.001 1.05 ,0.001
Female (yes vs. no) 0.47 ,0.001 0.47 ,0.001
Smoking (yes vs. no) 1.76 ,0.001
Diabetes (yes vs. no) 1.22 0.17
CVD history (yes vs. no) 3.03 ,0.001
BMI (kg/m2) 1.04 0.001
SBP (mmHg) 1.01 ,0.001
Cholesterol (mmol/L) 1.27 ,0.001
HR, hazard rate; UAE, urinary albumin excretion; CVD, cardiovascular disease; BMI, body mass index; SBP, systolic blood pressure.
Figure 2 Odds ratios for increased high-sensitive troponin T (.0.01 mg/L) (left panel) and increased N-terminal pro-B-type natriuretic
peptide (.125 ng/L) (right panel) per estimated glomerular filtration rate/albuminuria (urinary albumin excretion) class adjusted for age and
gender, reference category being estimated glomerular filtration rate 90–104 mL/min/1.73 m2 and UAE ,10 mg/24 h.
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subjects with impaired kidney function and/or higher albuminuria at
risk for cardiovascular events. These data, moreover, encourage
further research on the mechanism of how mild CKD is associated
with a worse cardiovascular outcome.
Strengths of this study are the use of a large prospective
community-based cohort with detailed information on many cov-
ariates. A limitation of the PREVEND cohort is that it includes a
predominantly Caucasian population and a relatively small
number of subjects with CKD stages 4 and higher (eGFR
,30 mL/min/1.73 m2). Our findings can therefore not be general-
ized to other populations, nor to subjects with severely impaired
kidney function. Furthermore, the PREVEND cohort is by design
enriched with subjects with higher albuminuria. Since sensitivity
analyses adjusting for the study design showed similar results,
this is not expected to have resulted in a bias.
In conclusion, hsTnT and NT-pro-BNP are increased in subjects
with a lower eGFR and/or higher albuminuria. Both cardiac damage
biomarkers are associated with ECG-assessed minor ischaemia and
left ventricular hypertrophy independent of eGFR and albuminuria.
In subjects with their impaired kidney function and/or albuminuria,
TnT and NT-pro-BNP are associated with cardiovascular outcome
independent of the level of the eGFR and albuminuria. These
effects are independent of cardiovascular risk factors. The
present study included only a limited number of subjects with
markedly reduced renal function. Notwithstanding, our data indi-
cate that increased levels of these cardiac biomarkers in subjects
with CKD stages 1/3 should be considered seriously and not be
discarded as merely the result of decreased renal clearance.
These data may furthermore help to dissect the mechanism by
which even mild chronic kidney disease results in cardiac damage.
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Supplementary material is available at European Heart Journal
online.
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Figure 3 Adjusted hazard ratios for cardiovascular events
according to CKD status and low- or high-sensitive troponin T
or N-terminal pro-B-type natriuretic peptide. Hazard ratios are
calculated with subjects with corresponding CKD status and
normal high-sensitive troponin T or N-terminal pro-B-type natri-
uretic peptide (,0.01 mg/L or ,125 ng/L, respectively) as refer-
ence groups. Adjusted hazard ratios are adjusted for age, gender,
history of cardiovascular disease, smoking, BMI, SBP, cholesterol
level and diabetes.
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Table 5 Hazard ratios for cardiovascular events with N-terminal pro-B-type natriuretic peptide as an independent
variable in various models adjusting for covariates
Variable Model 1 Model 2 Model 3 Model 4
HR P-value HR P-value HR P-value HR P-value
Ln NT-pro-BNP (ng/L) 1.57 ,0.001 1.31 ,0.001 1.22 ,0.001 1.17 ,0.001
eGFR (mL/min/1.73 m2) 0.98 ,0.001 0.99 0.18 0.99 0.06
Ln UAE (mg/24 h) 1.30 ,0.001 1.16 ,0.001 1.04 0.32
Age (year) 1.06 ,0.001 1.04 ,0.001
Female (yes vs. no) 0.40 ,0.001 0.41 ,0.001
Smoking (yes vs. no) 1.76 ,0.001
Diabetes (yes vs. no) 1.31 0.07
CVD history (yes vs. no) 2.68 ,0.001
BMI (kg/m2) 1.04 ,0.001
SBP (mmHg) 1.01 ,0.001
Cholesterol (mmol/L) 1.29 ,0.001
UAE, urinary albumin excretion; CVD, cardiovascular disease; BMI, body mass index; SBP, systolic blood pressure.
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A 50-year-old woman was referred with a
6-month history of dyspnoea. She presented
with obesity (body mass index: 40.9 kg/m2),
blood pressures of 140/80 mmHg on the right
arm and 100/70 mmHg on the left, a left sub-
clavian bruit, and corneal clouding covering the
pupil (Panel A). Laboratory tests were notable
for haemoglobin of 9.9 g/dL (normal: 12–16),
stomatocytes (Panel B) and a platelet count
of 78 000/mL (normal: 150 000–400 000).
C-reactive protein was normal. The total choles-
terol was 189 mg/dL (normal: ,200 mg/dL), tri-
glycerides were 265 mg/dL (normal: ,150),
HDL was 3 mg/dL (normal: .35), and
apolipoprotein-A1 was 11 mg/dL (normal:
105–205). Doppler-ultrasound and magnetic
resonance angiography demonstrated moderate
stenoses of the proximal left internal carotid
and subclavian arteries (Panel C). Echocardiog-
raphy showed normal pulmonary artery pres-
sures and left ventricular function. Coronary
angiography indicated mild left main stenosis
and a collateralized total occlusion of the right
coronary artery (Panel D); no inducible ischaemia was appreciated by dobutamine stress testing.
Based on the low HDL, diffuse atherosclerosis, and the stomatocytosis, we suspected an impairment of the ATP-binding cassette
transporter 1 protein. ABCA1 responsible for the cellular cholesterol and phospholipid efflux and may lead to vascular foam cell ac-
cumulation. Genetic analysis (electropherogram) identified an undescribed single heterozygote splice mutation of G. A (Panel E: ‘r’;
www.hgvs.org) at position 4274 of the cDNA (ABCA1 gene) targeting the donor splice site of the intron 30.
With no objective evidence of ischaemia to explain her dyspnoea and without neurological symptoms or exertional arm discomfort,
we elected to manage her vascular lesions medically. We targeted non-HDL goals with statin therapy and encouraged our patient to
lose weight and avoid drugs that may lower the HDL cholesterol. We arranged a familial genetic counselling and will follow her up
carefully.
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